Deals for the development and commercialisation of biosimilars have risen in prominence of late with the latest such deal being a global collaboration between Baxter International and Momenta Pharmaceuticals that covers up to six follow-on biologics. The partnership combines Baxter’s clinical development, biologics manufacturing and commercialisation capabilities with Momenta’s expertise in high-resolution analytics, characterisation and product and process development.